Intradiscal and Intra-articular Injection of Autologous Platelet-Rich-Plasma (PRP) in Patients With Lumbar Degenerative Disc Disease and Facet Joint Syndrome

Stylianos Kapetanakis

Status and phase: Not yet enrolling; Phase 3

Conditions: Degenerative Disc Disease; Facet Joint Syndrome

Treatments: Biological: Autologous PRP

Study type: Interventional

Funder types: Other

Identifiers

NCT04816747

Not administered

Details and patient eligibility

About

Autologous Platelet-Rich-Plasma (PRP) represents a regenerative therapy that has gained remarkable ground in the field of orthopaedics in recent years. PRP has been implemented for a plethora of musculoskeletal ailments, being associated with minor complications and noteworthy efficacy (Akeda et al., 2019). PRP has been depicted to contain a variety of growth factors crucial for regulation of cell proliferation and migration as well as extracellular matrix synthesis (Cheng et al., 2019). Furthermore, therapeutic effect of PRP administration is considered to be additionally exerted via its anti-inflammatory and immunoregulative properties, as it has been delineated to induce regional decrease of pro-inflammatory mediators at the injection site (Hirase et al., 2020).

Lumbar Degenerative Disc Disease (DDD) and Facet Joint Syndrome (FJS) constitute chronic degenerative conditions of lumbar spine that have been associated with substantial morbidity and disability in recent years. Besides the noted progress in comprehension of these conditions' pathogenesis, available therapeutic modalities remain extremely limited and controversial, being not capable of altering the natural progress of underlying disease (Wu et al., 2016; Wu et al., 2017; Hirase et al., 2020).

Autologous PRR has been recommended as a beneficial alternative instead of conventional treatment strategies for interventional management of lumbar DDD and FJS (Aufiero et al., 2015; Navani and Hames, 2015; Kirchner and Anitua, 2016; Levi et al., 2016; Tuakli-Wosornu et al., 2016; Wu et al., 2016; Akeda et al., 2017; Lutz GE, 2017; Wu et al., 2017; Cheng et al., 2019). Results of these studies indicated that intra-discal and intra-articular injection of PRP for DDD and FJS respectively is characterized by safety and satisfactory efficacy in reducing intensity of clinical manifestations, exerting also potentially regenerative effects. However, quality of available evidence is remarkably low, since in the overwhelming majority of these studies was a limited number of patients evaluated. Furthermore, determined follow-up intervals were not extended and, most importantly, patients were not majorly with rigorous clinical and radiologic criteria selected.

Aim of this study is to investigate the precise effects of intradiscal and intra-articular injection of PRP in patients with early-stage lumbar DDD and FJS, as determined by particular radiologic classifications. The prospective design, the defined greater number of recruited individuals in pilot analysis as well as the comparatively greater follow-up underline the originality of our protocol.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility criteria will be distinctly applied in participants with lumbar DDD and FJS prior to treatment application.

A. Participants with lumbar DDD

Inclusion Criteria

• Recurring low back pain persistent for more than 6 months demonstrating discogenic origin (i.e. localized at midline, exacerbated in seated position and alleviated in bed rest)
• Failure of initially implemented conservative measures (medication regimen and/or physical therapy sessions or other injections)
• Imaginary findings of Grade I-III DDD according to radiologic MRI-based classification proposed by Pfirrmann et al. (Pfirrmann et al., 2001)
• Absence of exclusion criteria, as defined below.

Exclusion Criteria

• Presence of local or systemic infection signs (clinical and laboratory)
• Concurrent known systemic inflammatory disease with musculoskeletal manifestations or other chronic inflammatory disease
• Concurrent known hemorrhagic disorder or antithrombotic regimen
• Presence of Grade IV-V DDD according to Pfirrmann classification (Pfirrmann et al., 2001)
• Spondylolysis/Spondylolisthesis
• Intervertebral Disc Herniation
• Previous spinal surgery
• Spinal Stenosis
• Primary or Secondary spinal tumour
• Spinal fracture in past 6 months
• Diagnosed psychiatric disorder
• Epidural steroid or other intradiscal injection or within past 30 days
• Administration of NSAIDs, steroids or dietary supplements with anti-inflammatory properties within past 30 days.

Β. Participants with lumbar FJS

Inclusion Criteria

• Recurring low back pain persistent for more than 6 months with no radiation to buttock or lower limb, presence of exacerbation in lateral bending, rotation and extension and paraspinal localization featuring reproduction with pressure.
• Failure of conservative treatment measures (medication regimen and/or physical therapy sessions or other injections).
• Radiologic findings of Grade I-II FJS according to CT-based classification proposed by Suri et al. (Suri et al., 2010)
• Absence of exclusion criteria, as designated below.

Exclusion Criteria

• Clinical manifestations of radiculopathy
• Presence of local or systemic infection signs (clinical and laboratory)
• Concurrent known systemic inflammatory disease with musculoskeletal manifestations or other chronic inflammatory disease
• Concurrent known hemorrhagic disorder or antithrombotic regimen.
• Presence of Grade III-IV FJS according to proposed classification of Suri et al. (Suri et al., 2010)
• Spondylolysis/Spondylolisthesis
• Intervertebral Disc Herniation
• Previous spinal surgery
• Spinal Stenosis
• Primary or Secondary spinal tumour
• Spinal fracture in past 6 months
• Diagnosed psychiatric disorder
• Previous intra-articular steroid injection within past 30 days
• Administration of NSAIDs, steroids or dietary supplements with anti-inflammatory properties within past 30 days.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Autologous PRP

Experimental group

Description:

Participants with diagnosed lumbar DDD are planned to be managed via intradiscal injection of 0.5-1 ml autologous PRP, whereas participants with FJS will be injected with 0.5 ml of respective solution. All procedures will be performed in surgical theatre under constant fluoroscopic guidance.

Treatment:

Biological: Autologous PRP